Video

Dr Chelsee Jensen Explains Implementing Biosimilars in Small vs Large Practices

Author(s):

Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.

Transcript

How does implementing tools for increasing biosimilar use differ between smaller and larger practices?

So, at a smaller practice site where maybe you're operating only in 1 state or maybe you just have a few commercial payers, or even if a majority of your payer mix is government payers, you can probably adopt biosimilars in a full fledge swoop. So, all at once vs our approach, which has been a phased approach of initiating new patients on biosimilars and then choosing a biosimilar at prior authorization renewal. So, if you're in a smaller health system, and you're able to pick a preferred product—because, again, maybe your payer landscape is more standardized—then you can have one set implementation date, have reduced inventory burden, and just improve workflows going forward.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
Hadar Avihai Lev-Tov, MD
Ayodeji Adegunsoye, MD, PhD, MSc
David J. Maron, MD, FASPC, Stanford University School of Medicine
Hadar Avihai Lev-Tov, MD
Senator Vincent Polistina (R, New Jersey)
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo